Alkermes plc

ALKS Healthcare Drug Manufacturers Specialty & Generic

Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024.

Revenue
+21.8%
EPS
−80.6%
Free cash flow
+6.78%

Quarter to September 2026, against a year earlier

44.61 1.28 −2.79%
Market cap
$7.5B
P/E
0.0×
Fwd P/E
−85.9×
Dividend yield
—
F-score
7/9
Altman Z
5.33
Beneish M
−3.29
Dividend safety
n/a

Alkermes plc (ALKS) Net margin

Alert me on Net margin

Alkermes plc's net margin over the twelve months to 30 September 2026 was −0.02%, down 16.4 percentage points from fiscal 2025 (16.4%). Over the past ten years it has ranged from −36.2% (fiscal 2015) to 23.6% (fiscal 2024); the current reading is higher than 82% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of −2.45% and below the Healthcare sector median of 0.00%.

Net margin, annual

Embed this chart

Annual newest first

Period Net margin Change (points)
FY2025 16.4% (7.20)
FY2024 23.6% 2.18
FY2023 21.4% 35.63
FY2022 −14.2% (10.14)
FY2021 −4.10% 6.57
FY2020 −10.7% 6.12
FY2019 −16.8% (4.06)
FY2018 −12.7% 4.75
FY2017 −17.5% 10.47
FY2016 −28.0% 8.20

Quarterly newest first

Period Net margin Change (points)
Sep 2026 3.39% 3.29
Jun 2026 0.10% 17.02
Mar 2026 −16.9% (29.75)
Dec 2025 12.8% (8.17)
43 more quarters

Against its own ten years

Low −36.2% High 23.6%
Ten-year median −12.7%
Current reading's percentile 70

Net margin against peers

What Net margin is

Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.

Net Income Allotted to Shareholders ÷ Revenue

The full definition of Net margin →

More on ALKS